Gain Therapeutics Inc. (GANX)
NASDAQ: GANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GANX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $44.50M
- EPS (TTM)
- -$0.42
- Dividend yield
- None
- 52-week range
- 0.94 – 4.34
- Day range
- 0.9701 – 1.10
- Volume / Avg
- 559.73K / 550.22K
- Beta
- —
- Shares outstanding
- 44.53M
52-week range
GANX stock today
On Nov 20, GANX ended the session at $0.9994, shedding $0.0506 (4.82%), versus the S&P 500's 3.70% decline. At this level, GANX sits near the bottom of its 52-week range of $0.94 to $4.34: 77.0% below the high, set on Dec 11, 2025 and 6.3% above the low. GANX is down 69.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.4%.
Gain Therapeutics has posted a net loss over the last twelve months (EPS of -$0.42), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Gain Therapeutics
Company profileGain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Gene Mack M.B.A.
- Headquarters
- Bethesda, MD
- Employees
- 20
- IPO year
- 2021
- Website
- gaintherapeutics.com
Financial highlights
Full financialsGain Therapeutics reported a net loss of $20.2 million, compared with a loss of $20.4 million a year earlier. Diluted earnings per share came in at -$0.61.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $55.18K | $140.11K | $164.99K |
| Growth | — | — | -60.62% | -15.08% | +471.29% |
| Net income | $-20.16M | $-20.41M | $-22.27M | $-17.59M | $-13.89M |
| EPS (diluted) | $-0.61 | $-0.89 | $-1.71 | $-1.48 | $-1.37 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$7.20+620.43%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.07 vs $-0.13
- Surprise
- +46.15%
GANX news
All GANX news- Gain Therapeutics, Inc. Reports Phase 1b Clinical Data for RexaceractNasdaq
- Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686GlobeNewswire
- Gain Therapeutics Q3 Loss NarrowsNasdaq
- Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate UpdateGlobeNewswire
- Gain Therapeutics, Inc. Appoints Jeanette Weidner as Vice President, Finance, Effective October 28, 2026NasdaqGANX, BF.B
Gain Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QUCYQuantum Cyber N.V. | 0.512 | -7.25% | $44.67M | vs GANX |
| ANVSAnnovis Bio Inc. | 0.7113 | -4.96% | $44.12M | vs GANX |
| APLMApollomics Inc. Class A | 15.54 | -6.92% | $45.28M | vs GANX |
| RNXTRenovoRx Inc. | 0.942 | -10.29% | $45.45M | vs GANX |
| RLYBRallybio Corporation | 15.47 | -0.32% | $43.32M | vs GANX |
| SPROSpero Therapeutics Inc. | 0.742 | -10.20% | $43.23M | vs GANX |
| HOWLWerewolf Therapeutics Inc. | 0.9466 | -3.97% | $46.00M | vs GANX |
| MISTMilestone Pharmaceuticals Inc. | 0.3711 | -7.06% | $46.20M | vs GANX |
Indexes, lists and sector
Gain Therapeutics stock FAQ
What is Gain Therapeutics's stock price today?
GANX last traded at $0.9994 as of Nov 20, 4:00 PM EST, down 4.82% on the day. Prices are delayed at least 15 minutes.
Who is Gain Therapeutics's CEO?
Mr. Gene Mack M.B.A. is the chief executive officer of Gain Therapeutics Inc., which has about 20 employees.
What is the GANX 52-week high?
The 52-week high for GANX is $4.34 and the 52-week low is $0.94. The stock is currently 77.0% below its high.